Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSTU:SMZ1 -4.07%86 EV-to-FCF is 11.74 as of Jul. 14, 2026, which is 50% below its 10-year median of 23.36. GuruFocus rates STU:SMZ1 with a GF Score™ of 86/100 and a GF Value™ of €0.53 (Fairly Valued). The stock has 4 warning signs investors should review. Among 335 Biotechnology companies, Sino Biopharmaceutical ranks better than 57.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sino Biopharmaceutical's Enterprise Value is €10,789 Mil.
Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €919 Mil. Therefore, Sino Biopharmaceutical's EV-to-FCF for today is 11.74.
The historical rank and industry rank for Sino Biopharmaceutical's EV-to-FCF or its related term are showing as below:
STU:SMZ1'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.77 Med: 23.36 Max: 52.01
Current: 11.54
During the past 13 years, the highest EV-to-FCF of Sino Biopharmaceutical was 52.01. The lowest was 9.77. And the median was 23.36.
STU:SMZ1's EV-to-FCF is ranked better than 57.01% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs STU:SMZ1: 11.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sino Biopharmaceutical (STU:SMZ1) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sino Biopharmaceutical's PE Ratio (TTM) for today is calculated as:
Sino Biopharmaceutical's share price for today is €0.5686.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.016.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:SMZ1 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's EV-to-FCF falls into.
Sino Biopharmaceutical's current Enterprise Value is €10,789 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €919 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (STU:SMZ1) has a EV-to-FCF of 11.74 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sino Biopharmaceutical and its competitors. This is 50% below median its historical median of 23.36. Over the past decade, Sino Biopharmaceutical's EV-to-FCF has ranged from 9.77 to 52.01. According to the industry distribution chart, Sino Biopharmaceutical ranks #144 out of 335 companies in the Biotechnology industry, placing it in the top 43%.
Is Sino Biopharmaceutical's EV-to-FCF too high?
Sino Biopharmaceutical's current EV-to-FCF of 11.74 is 50% below median its 10-year median of 23.36. Over the past 10 years, this metric has ranged from a low of 9.77 to a high of 52.01. The Biotechnology industry median EV-to-FCF is 15.34. Sino Biopharmaceutical's value of 11.74 is 23.5% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #144 out of 335 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #144 out of 335 companies for EV-to-FCF. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median EV-to-FCF is 15.34. Sino Biopharmaceutical's value of 11.74 is 23.5% below this benchmark. Historically, Sino Biopharmaceutical's own EV-to-FCF has ranged from 9.77 to 52.01 over the past decade. While the company's 10-year median is 23.36 vs. the industry median of 15.34, Sino Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current EV-to-FCF of 11.74 is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current EV-to-FCF is 11.74, which is 50% below median its own 10-year median of 23.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (STU:SMZ1) is currently considered Fairly Valued. The stock's GF Value™ is €0.53, compared to a current price of €0.57 — trading 7.3% above its estimated fair value. The current EV-to-FCF is 11.74, which is 50% below median its 10-year median of 23.36 and 23.5% below the Biotechnology industry median of 15.34. Sino Biopharmaceutical's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sino Biopharmaceutical (STU:SMZ1), the current EV-to-FCF is 11.74 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (STU:SMZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of €0.57 is trading 7.3% above its estimated GF Value™ of €0.53.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for STU:SMZ1:
EV-to-FCF: 11.74 (50% below median its 10-year median of 23.36)
GF Value™: €0.53 vs. price of €0.57 (7.3% above fair value)
Industry Position: 23.5% below the Biotechnology median (#144 of 335)
No single metric tells the full story. See the STU:SMZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
86GF Score
Get the complete analysis for STU:SMZ1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SMZ1 has been successfully added to your 
